Navigation Links
Pearl Therapeutics Advances Its Long-Acting Bronchodilator Combination Product Candidate into Four Additional Phase 2 Studies
Date:6/16/2011

REDWOOD CITY, Calif., June 16, 2011 /PRNewswire/ -- Pearl Therapeutics Inc. today announced the advancement of its dual combination product candidate, PT003 and its individual components, PT001 and PT005 into a series of planned Phase 2 studies in patients with moderate-to-severe COPD. PT003 (GFF MDI) is an investigational inhaled combination bronchodilator product comprising glycopyrrolate (GP), a long-acting muscarinic antagonist (LAMA), and formoterol (FF), a well-known, established, long-acting beta-2 agonist (LABA), delivered together for the first time via a hydrofluoroalkane metered dose inhaler (HFA MDI), using a proprietary cosuspension formulation approach. These Phase 2 studies are designed to expand findings from the Company's recently concluded Phase 2b study of PT003 and strengthen the safety and efficacy foundation of the Company's Phase 3 program, which is expected to start in late 2012. Specifically they will provide further insight into the individual component doses, compare clinical activity to that of a short-acting anticholinergic agent and assess any cardiovascular effects.

The Phase 2 studies in this series include:

  1. A randomized, double-blind study of four doses of PT001 (GP MDI) compared to placebo and Atrovent® HFA inhalation aerosol, a short-acting muscarinic antagonist;
  2. A randomized, double-blind study of three doses of PT005 (FF MDI) compared to placebo and Foradil® Aerolizer®;
  3. A randomized, double-blind cardiovascular safety study of PT003, PT005, PT001 and Foradil® Aerolizer®; and
  4. A randomized, double-blind study of four doses of PT003 compared with its components, PT001 and PT005.

"With the success of our first Phase 2b study behind us, we are advancing PT003 and its components without delay into this planned series of four Phase 2 studies," said Chuck Bramlage, P
'/>"/>

SOURCE Pearl Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pearl Therapeutics Phase 2b Results Show a 50% Improvement in Lung Function with PT003 Compared to Spiriva® and Foradil® in Patients with COPD
2. Asante Solutions Receives FDA Clearance for Pearl™ Insulin Pump
3. Pearl Therapeutics Highlights Its Porous Particle Cosuspension Platform, Demonstrating Universal Applicability Across Multiple Drug Classes and Combination Products
4. Pearl Therapeutics to Present Complete PT003 Results from Phase 2b COPD Study in a Late-Breaker Session at the American Thoracic Society Annual Meeting
5. Asante Solutions, Inc. Receives CE Mark for Pearl™ Insulin Pump
6. Sanofi Enters Into Research Collaboration With Biopharmaceutical Company Audion Therapeutics to Develop Potential Treatments for Hearing Loss
7. Cardinal Health, Prime Therapeutics Renew Primary Distribution Agreement
8. Cell Therapeutics Completes Type A Meeting With FDAs Division of Oncology Drug Products: Guidance Provided for Resubmission of Pixantrone NDA for Consideration of Accelerated Approval
9. Novelos Therapeutics to Present at the 5th Lippert/Heilshorn Life Sciences & Medical Technologies Virtual Conference on June 16
10. Grifols Announces Combined Operations With Talecris to Begin a New Era as a Global Leader of Life-Saving Plasma Therapeutics
11. Healthpoint Biotherapeutics to Present at Upcoming Investment Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)...   ViaDerma, Inc. (OTCQB: VDRM), a ... to market, has recently released a revolutionary new ... topical liquid tetracycline-based antibiotic that uses a patent-pending ... medication active ingredients into topical drugs. The drug ... to help prevent skin infection in minor cuts, ...
(Date:10/30/2014)... , Oct. 30, 2014  Nektar Therapeutics (Nasdaq: ... the third quarter ended September 30, 2014 on Thursday, ... markets. Howard Robin , president and chief executive ... results beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. ... and a live audio-only Webcast of the conference call ...
(Date:10/30/2014)...   BioLife Solutions , Inc. (NASDAQ: ... proprietary clinical grade hypothermic storage and ... products for cells and tissues, today announced today ... be released on Thursday, November 6, 2014, and that ... webcast at 1:30 p.m. PST that afternoon. Management will ...
Breaking Medicine Technology:ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 3Nektar to Announce Financial Results for the Third Quarter 2014 on Thursday, November 6, 2014, After Close of U.S.-Based Financial Markets 2BioLife Solutions to Report Financial Results for Third Quarter 2014 and Provide Business Update on November 6, 2014 2
... Support Development,of Omega DUROS Continuous Delivery Therapy, ... Intarcia,Therapeutics, Inc., a privately held biopharmaceutical company,today ... study of omega,interferon with or without ribavirin ... C. The results demonstrate that,omega interferon in ...
... Conn., April 12, 2007 /PRNewswire-FirstCall/ --,CuraGen Corporation ... (PXD101), a histone deacetylase (HDAC) inhibitor being,investigated ... a protein,being investigated for the prevention of ... upcoming American Association for Cancer,Research (AACR) 2007 ...
Cached Medicine Technology:Intarcia Therapeutics Announces Final Results From a Phase 2 Study,of Injectable Omega Interferon plus Ribavirin for the Treatment of,Hepatitis C Genotype-1 2Intarcia Therapeutics Announces Final Results From a Phase 2 Study,of Injectable Omega Interferon plus Ribavirin for the Treatment of,Hepatitis C Genotype-1 3Intarcia Therapeutics Announces Final Results From a Phase 2 Study,of Injectable Omega Interferon plus Ribavirin for the Treatment of,Hepatitis C Genotype-1 4CuraGen Announces New Preclinical Results with Belinostat and,Velafermin to be Presented at AACR Annual Meeting 2CuraGen Announces New Preclinical Results with Belinostat and,Velafermin to be Presented at AACR Annual Meeting 3CuraGen Announces New Preclinical Results with Belinostat and,Velafermin to be Presented at AACR Annual Meeting 4
(Date:10/30/2014)... Dr. Joseph Furlin MD, a certified obstetrician and gynecologist, has ... GYN in Melrose Park, IL and OB GYN ... about each of the care services and practice areas that ... and Spanish. The navigation of the website is easy ... Dr. Furlin’s patients with important information regarding his care methods ...
(Date:10/30/2014)... 2014 Global prebiotics market is expected ... a new study by Grand View Research, Inc. Positive ... sugar and fat free products owing to increased concerns ... prebiotics over the forecast period. , View full report ... & beverage was the largest application segment with market ...
(Date:10/30/2014)... 2014 REV'D Provision Co. announced today ... through a unique service called, The Feed . ... the everyday athlete. The Feed has taken the nutritional ... a system to pass that information on to the ... now available on The Feed!” says REV’D® marketing manager ...
(Date:10/30/2014)... New York (PRWEB) October 30, 2014 ... Society (NAMS) came to a close on Saturday, ... meeting since the Society’s inception in 1989. NAMS is ... health and quality of life of all women during ... healthy aging. With over 2,000 physicians and thought leaders ...
(Date:10/30/2014)... 2014 Sound Telecom, a leader in the ... assist people any time they wonder, “Should I use an ... by leading them through a series of yes or no ... query. , There are many considerations and scenarios that come ... answering service . This decision infographic serves as a ...
Breaking Medicine News(10 mins):Health News:Dr. Joseph Furlin Launches New Website with Information about Care Services 2Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 2Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 3Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 4Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 5Health News:Nutrition Experts at TheFeed.com Get REV'D 2Health News:Nutrition Experts at TheFeed.com Get REV'D 3Health News:Highlights from The North American Menopause Society 25th Annual Meeting 2Health News:Highlights from The North American Menopause Society 25th Annual Meeting 3Health News:Sound Telecom Produces Decision Infographic to Aid Businesses 2
... disorder, arterial trouble , FRIDAY, Oct. 12 (HealthDay News) ... pressure (CPAP) to treat people with obstructive sleep apnea ... the arteries -- within months, a new study finds. ... a direct link between obstructive sleep apnea and atherosclerosis, ...
... Calif., Oct. 12 Yesterday,Governor Schwarzenegger signed into ... to service and extend benefits to children and ... permanency. One important bill in this,package of legislation ... the current system of group home care into ...
... 12 The Agency for,Healthcare Research and Quality, part ... today the award of $41.6 million over the next ... centers as part of its,Centers for Education and Research ... the CERTs program. "Expanding the Centers for Education ...
... Shown to Prevent Post-Meal Oxidative Stress, FRESNO, Calif., ... It is probably a good idea based on health ... Health Effects of,Fruits and Vegetables in Houston, Texas this ... foods should be,consumed with each meal to prevent periods ...
... with the confusion of ... to their children, CINCINNATI, Oct. 12 All too ... give our children, especially,when it comes to the readily available ... as a frightening, but,important reminder that no medicine comes without ...
... Prior to Stroke, CLEVELAND, Oct. 12 Carotid ... today, are a significant risk factor,for stroke but many ... ultrasound screening is a successful tool for revealing,blocked carotid ... before death or,disability occurs. Life Line Screening, the ...
Cached Medicine News:Health News:Sleep Apnea Treatment Helps Stave Off Heart Disease 2Health News:California Alliance Applauds Governor's Support of Group Home Reform for Foster Youth 2Health News:California Alliance Applauds Governor's Support of Group Home Reform for Foster Youth 3Health News:AHRQ Expands Therapeutics Education and Research Centers and Adds New Topics: Health IT, Economics, Formularies 2Health News:AHRQ Expands Therapeutics Education and Research Centers and Adds New Topics: Health IT, Economics, Formularies 3Health News:Grape Consumption Improves Antioxidant Capacity in Humans 2Health News:Dr. Laura Jana Offers Parents Five Key Ways to Ensure Accurate Dosing of Liquid Medication to Infants 2Health News:Dr. Laura Jana Offers Parents Five Key Ways to Ensure Accurate Dosing of Liquid Medication to Infants 3Health News:Dr. Laura Jana Offers Parents Five Key Ways to Ensure Accurate Dosing of Liquid Medication to Infants 4Health News:Asymptomatic Carotid Artery Blockage a Significant Stroke Risk 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: